Omalizumab Therapy for Allergic Bronchopulmonary Aspergillosis in Children with Cystic Fibrosis: A Synthesis of Published Evidence

被引：51

作者：

Tanou, Kalliopi ^{[1
,2
]}

Zintzaras, Elias ^{[3
,4
]}

Kaditis, Athanasios G. ^{[1
,2
]}

机构：

[1] Univ Athens, Sch Med, Dept Pediat 1, Pediat Pulmonol Unit, GR-11527 Athens, Greece

[2] Aghia Sophia Childrens Hosp, Athens, Greece

[3] Tufts Univ, Sch Med, Tufts Med Ctr, Ctr Clin Evidence Synth,Inst Clin Res & Hlth Poli, Boston, MA 02111 USA

[4] Univ Thessaly, Sch Med, Dept Biomath, Larisa, Greece

来源：

PEDIATRIC PULMONOLOGY | 2014年 / 49卷 / 05期

关键词：

ABPA; A; fumigatus; anti-IgE; ANTI-IGE ANTIBODY; ABPA; CF;

D O I：

10.1002/ppul.22937

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis (CF) is treated with corticosteroids. Since elevated IgE is a cardinal abnormality, anti-IgE has been used sporadically as adjuvant treatment. In eight case reports, 13 children with CF and ABPA received anti-IgE resulting in improved FEV1, fewer respiratory symptoms and decreased corticosteroid use. Pediatr Pulmonol. 2014; 49:503-507. (c) 2013 Wiley Periodicals, Inc.

引用

页码：503 / 507

页数：5

共 13 条

[11] Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody [J].